TargetMol

Ecraprost

Product Code:
 
TAR-T25362
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T25362-5mg5mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T25362-50mg50mg£2,625.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T25362-100mg100mg£3,524.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Ecraprost is used as a prodrug of prostaglandin E1.
CAS:
136892-64-3
Formula:
C28H48O6
Molecular Weight:
480.686
Purity:
0.98
SMILES:
CCCCC[C@H](O)C=C[C@H]1[C@H](O)CC(OC(=O)CCC)=C1CCCCCCC(=O)OCCCC

References

1. Nehler MR, Brass EP, Anthony R, Dormandy J, Jiao J, McNamara TO, Hiatt WR; Circulase investigators. Adjunctive parenteral therapy with lipo-ecraprost, a prostaglandin E1 analog, in patients with critical limb ischemia undergoing distal revascularization does not improve 6-month outcomes. J Vasc Surg. 2007 May;45(5):953-60; discussion 960-1. Epub 2007 Mar 9. PubMed PMID: 17350216. 2. Ecraprost: AS 013, Circulase. Drugs R D. 2004;5(1):31-4. Review. PubMed PMID: 14725489. 3. Brass EP, Anthony R, Dormandy J, Hiatt WR, Jiao J, Nakanishi A, McNamara T, Nehler M; Circulase investigators. Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia. J Vasc Surg. 2006 Apr;43(4):752-9. PubMed PMID: 16616232. 4. Robertson L, Ghouri MA, Kovacs F. Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment. Cochrane Database Syst Rev. 2012 Aug 15;(8):CD002071. doi: 10.1002/14651858.CD002071.pub3. Review. PubMed PMID: 22895926.